Sirotich, Emily http://orcid.org/0000-0002-7087-8543
Nazaryan, Hasmik
Chowdhury, Saifur Rahman
Guyatt, Gordon
Agarwal, Arnav
Leong, Russell
Wen, Aaron
Xu, Emily
Liu, Bonnie
Pallapothu, Sushmitha
Rathod, Preksha
Kwon, Henry Y.
Dookie, Jared
Shafiee, Amirmohammad
Charness, Jay
DiRaimo, Jennifer
Paynter, Dale
Pruitt, Barbara
Strachan, Gail
Couban, Rachel
Ye, Zhikang
Arnold, Donald M.
Funding for this research was provided by:
Canadian Institutes of Health Research (165811)
Article History
Received: 14 March 2022
Accepted: 13 December 2023
First Online: 6 January 2024
Declarations
:
: Not applicable.
: Consent for publication was received from all authors.
: DA has no relevant conflicts of interest; receives research funding for non-relevant work: Novartis; Consultancy: Novartis, Amgen, UCB, Principia, and Rigel. Other authors declare they have no competing interests. NC: Honoraria for advisory board and educational events: Novartis, Amgen, UCB, Rigel, Principia. Research support: Novartis, Rigel. AC: Consulting fees from Synergy; the institution has received research support on his behalf from Novartis, Novo Nordisk, Pfizer, Sanofi, Spark, and Takeda. SGF: Speaker for Amgen, Novartis and Dova. RFG: No relevant conflicts of interest. Research funding for non-relevant work: Novartis, Pfizer, Agios; advisory board: Dova. CEB, VB, KdW, ZH, JC, JD, DP, BP, RC, GS, CFM, CO, MP, SCP, KEW, JWY, and JGK declare that they have no competing interests. MK: Consulting fees and honoraria from Amgen, Bristol-Myer Squibb, Gilead, Janssen. DMA: Honoraria for advisory board, consultancy, and educational events: Novartis, Amgen, Medison, Sobi, Principia. Research support: Novartis, Rigel.